1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,500 | 0,540 | 16:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.03. | IMMUNEONCO-B (01541): DATE OF BOARD MEETING | 1 | HKEx | ||
| 06.03. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - (1) UNUSUAL PRICE MOVEMENTS; AND (2) APPROVAL OF IND APPLICATION OF IMM0306S (SUBCUTANEOUS FORMULATION) ... | - | HKEx | ||
| 10.02. | IMMUNEONCO-B (01541): CONNECTED TRANSACTION - THE LOAN AGREEMENT | 2 | HKEx | ||
| IMMUNEONCO BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 21.01. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) | 3 | HKEx | ||
| 12.01. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) FOR ATHEROSCLEROSIS | - | HKEx | ||
| 06.01. | Instil Bio und ImmuneOnco lösen Lizenzvereinbarung auf | 11 | Investing.com Deutsch | ||
| 06.01. | Instil's stock sinks after it clears out pipeline, hands 2 drugs back to ImmuneOnco | 4 | FierceBiotech | ||
| 06.01. | IMMUNEONCO-B (01541): INSIDE INFORMATION - IMMUNEONCO TO REGAIN GLOBAL RIGHTS TO IMM2510 AND IMM27M | - | HKEx | ||
| 06.01. | Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco | 205 | GlobeNewswire (Europe) | DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) ("Instil") today announced that Axion Bio, Inc. ("Axion"), a wholly-owned subsidiary of Instil, has decided to discontinue... ► Artikel lesen | |
| 03.12.25 | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY EXECUTIVE DIRECTOR, CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD | 5 | HKEx | ||
| 27.11.25 | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - APPROVAL OF THE PHASE III CLINICAL STUDY PROTOCAL OF IMM0306 FOR THE TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR ... | 1 | HKEx | ||
| 20.11.25 | IMMUNEONCO-B (01541): DISCLOSEABLE TRANSACTIONS - REDEMPTIONS AND SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS | 2 | HKEx | ||
| 17.11.25 | IMMUNEONCO-B (01541): ARTICLES OF ASSOCIATION | 2 | HKEx | ||
| 17.11.25 | IMMUNEONCO-B (01541): AMENDMENTS TO THE ARTICLES OF ASSOCIATION | 2 | HKEx | ||
| 07.11.25 | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY EXECUTIVE DIRECTOR, CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD | 2 | HKEx | ||
| 23.10.25 | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATENT DOSED IN THE PHASE IB/II CLINICAL TRIAL OF IMM2510 IN COMBINATION WITH IMM01 | - | HKEx | ||
| 16.10.25 | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 16.10.25 | IMMUNEONCO-B (01541): COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 09.10.25 | BRIEF: ImmuneOnco to raise $45 million via share placement at 13% discount | 2 | Bamboo Works | ||
| 09.10.25 | IMMUNEONCO-B (01541): PLACING OF NEW H SHARES UNDER GENERAL MANDATE | 2 | HKEx |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 1,759 | +1,24 % | Ocugen, Inc. - 8-K, Current Report | ||
| VIKING THERAPEUTICS | 27,835 | -0,50 % | Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics | ||
| EDITAS MEDICINE | 2,053 | +1,68 % | Is Editas Medicine Going to $0? | ||
| SAREPTA THERAPEUTICS | 14,710 | +1,62 % | Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies | ||
| EXACT SCIENCES | 90,94 | +0,22 % | Abbott to close $21B Exact Sciences deal on March 23 | ||
| BASILEA | 56,90 | -0,70 % | BANCO BILBAO VIZCAYA ARGENTARIA, S.A.: The Company reports the 2025 "Prudential Relevance Report" (Pilar III Basilea) | ||
| TELIX PHARMACEUTICALS | 8,008 | +2,01 % | IBA SA: Telix selects IBA Cyclone KIUBE to support manufacturing expansion in the U.S. | Louvain-la-Neuve, Belgium- March 20, 2026 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of radiopharmaceutical... ► Artikel lesen | |
| REPLIGEN | 97,00 | -0,47 % | Repligen Corporation: Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year... ► Artikel lesen | |
| UNIQURE | 13,755 | -1,43 % | uniQure Inc.: uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease | LEXINGTON, Mass. and AMSTERDAM, March 02, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs... ► Artikel lesen | |
| CODEXIS | 1,355 | -2,38 % | Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis Manufacturing Platform | REDWOOD CITY, Calif., March 4, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced... ► Artikel lesen | |
| ORUKA THERAPEUTICS | 36,000 | +6,51 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated... ► Artikel lesen | |
| MACROGENICS | 2,426 | -1,78 % | MacroGenics, Inc.: MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures | Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026Lorigerlimab Phase 2 LINNET study update in mid-2026IND submission for MGC030... ► Artikel lesen | |
| OMEROS | 9,600 | +0,52 % | Omeros Corporation: Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment | Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22,... ► Artikel lesen | |
| SPERO THERAPEUTICS | 2,040 | -0,73 % | Spero Therapeutics, Inc.: Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026 | ||
| KALVISTA PHARMACEUTICALS | 14,700 | -0,68 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present New EKTERLY (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference | New interim data from the KONFIDENT-KID trial evaluating sebetralstat in children aged 2-11 accepted for late-breaking oral presentation KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced... ► Artikel lesen |
Das Unternehmen IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,059 (-11,03 %) liegt der Kurs bei 0,476 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC finden Sie auf Wallstreet Online.